Mr. Rubin serves as Executive Director for No Patient Left Behind (NPLB), a non-profit dedicated to creating and maintaining patient access to affordable prescription drugs.

With more than 20 years of health policy, strategic advocacy, and public affairs experience, Mr. Rubin has held senior-level positions spanning public and private sector payers, innovators, and regulators. His experience includes working for United Healthcare’s Medicare business and leading Aetna’s federal government affairs team during implementation of the Affordable Care Act.  He also has worked for biopharma companies where he advised the entities on a range of policy and regulatory issues. 

Mr. Rubin’s government experience includes serving as Majority Staff Director for the U.S. Senate Committee on Health, Education, Labor, and Pensions Subcommittee on Retirement and Aging and Legislative Director for a senior member of the U.S. House Ways and Means and Budget Committees.

He can be reached via prubin@nopatientleftbehind.org.

Lynda Gorov is executive editor of No Patient Left Behind. A veteran reporter and editor, she has covered everything from urban affairs to Afghanistan after 9-11 for The Boston Globe, among other news outlets, documented her own encounters with cancer and the healthcare system, and overseen teams of journalists worldwide. She is based in Los Angeles.

Jessica Sagers is a scientist, investor, and writer passionate about leveling our society's unequal playing fields. After growing up in the Utah mountains, she received her PhD from Harvard University where she championed the causes of women in STEM as President of Harvard Graduate Women in Science and Engineering (HGWISE) and conducted NIH-funded research on hearing loss. At RA Capital Management, Jessica created and holds the role of Head of Engagement, blending her skills as a scientist, investor, and communicator to make difficult ideas understandable. She often writes and speaks on how science, policy, insurance, and capital can complement one another in a biomedical ecosystem that invents new medicines and makes them affordable to all patients who need them. Her research has been published in many peer-reviewed journals and her opinions have been featured in outlets including Science, Nature, STAT News, Timmerman Report, and RealClearHealth.

Jim Greenwood is a former house parent and caseworker helping disabled and abused children. At the age of 29 he was elected to the Pennsylvania House of Representatives where he formed the Legislative Children’s Caucus. After six years in the State House he was elected to the State Senate and six years later to Congress. During his 12 years in Congress Greenwood was a leader on healthcare, reproductive rights and environmental issues, and as Chair of the Energy and Commerce Committee Subcommittee on Oversight and Investigation, he led investigations into Enron, Global Crossings, WorldCom, Imclone, nuclear waste cleanup and government waste fraud and abuse. From 2005 through 2020 Greenwood served as the President and CEO of the Biotechnology Innovation Organization and grew it into a world-class trade association for more than 1,000 biopharmaceutical companies. He currently chairs the Life Sciences Health, Policy and Regulatory Group at the DLA Piper law firm and serves as an advisor to RA Capital.

Sara Nayeem is a mother, investor, and advocate for the biomedical innovation ecosystem. Sara received her AB in Biology from Harvard University, and then went on to experiences that spanned the medical, financial, and entrepreneurial worlds. She worked as an investment banking analyst at Morgan Stanley while deferring medical school at Yale University. Drawn to the business and policy aspects of medicine, she decided to pursue an MD / MBA at Yale, eventually going back into investment banking in Merrill Lynch’s healthcare group. Sara then found her way to venture capital at New Enterprise Associates, where she focuses on biopharmaceutical investments. On Twitter (@SaraNayeem) and as a board member of NPLB, the New England Venture Capital Association, and Incubate Coalition, Sara advocates for the innovation ecosystem, improved patient access to medical therapies, and diversity and inclusion in the biopharma industry.

Keith Murphy is a scientist, inventor, and entrepreneur who has focused on advancing breakthrough medical technologies. He studied chemical engineering at MIT and worked on successful drug development, first for kids for pituitary deficiencies at Alkermes in Massachusetts, and then for cancer and osteoporosis at Amgen in California. He has founded multiple companies in San Diego based on 3D bioprinting, a field in which he has been pioneering for over a decade. He is an inventor of the NovoGen MMX bioprinter, which was named alongside the iPad as one of the best inventions of 2010 by TIME Magazine. His first company and its products won numerous accolades including the company being named as a 2015 Technology Pioneer by the World Economic Forum in Davos. He has been recognized as one of the most influential people in the world in the stem cell field and he and his companies have been featured in the Economist, the Wall St. Journal, Forbes, Wired, Popular Science, and on CNBC.

David seeks to balance family, work, and volunteer work, and sometimes succeeds. He is married to Elizabeth, a fellow lawyer who spent a decade working to provide benefits to parents, and has two daughters, a healthcare/biotech communications professional and an immigration lawyer in the San Francisco Public Defender's office. David split his business career between government and the biotechnology industry. He was fortunate to be able to serve in senior positions in both state and federal government, including in the White House and in legal positions on the U.S. House of Representatives Committee, on the Judiciary, in a state legislature, and as a member of the California State Commission on economic issues and government reform. David has served on three committees for the National Academy of Medicine. He served as a senior corporate officer for long periods at both Genentech and Amgen. David is Managing Director of Bay City Capital, a San Francisco-based life science venture firm. He is active in the nonprofit world as a hospital board member (UCSF Benioff Children’s Hospitals) and is a frequent author of policy-oriented opinion pieces in journals such as Harvard Business Review, STAT News, Forbes, Morning Consult, The Hill, and Health Affairs.

Gunnar Esiason is a rare disease patient leader, whose recovery from near end-stage cystic fibrosis thanks to a pharmaceutical breakthrough has motivated his desire to see cures delivered to the millions living with unmet medical needs. He is a joint degree MBA/MPH student at Dartmouth College and is passionate about early stage drug development, patient empowerment and health policy. Outside of his academic work, he has consulted on clinical trial development, a real-world evidence population health study, and a cystic fibrosis-specific mental health and wellness screening tool. Gunnar has been a featured keynote speaker at top medical centers and health industry events, and also delivered the 2019 pre-commencement address at the St. Louis University School of Medicine. Gunnar is the director of patient outreach at the Boomer Esiason Foundation, a writer, podcaster, dog dad, and an above-average hockey player, but below-average skier. His health policy opinions have been featured in US News & World Report, Newsweek, The Hill, RealClear Politics, and Morning Consult.

Patricia “Pat” Fraser is the U.S.-born child of Afro-Caribbean immigrants, indoctrinated at an early age to work hard in school because educational achievements were seen as the door to success and the American dream. To that end, she completed degrees in both public health and medicine. Pat spent time in academia, conducting NIH-sponsored research to study the possible genetic and environmental factors that may account for the disproportionate risk of systemic lupus erythematosus in African-American women, one of the many health disparities observed among U.S. populations. These days, Pat sees patients part-time in her rheumatology practice at Brigham and Women’s Hospital. During the remainder of her work week, she works as a safety physician at Sanofi Genzyme.

D.A. Wallach is a venture capital investor and an acclaimed recording artist. Discovered by Kanye West while he was an undergraduate at Harvard, D.A. began his career as one half of the duo Chester French, releasing two full-length albums through Interscope Records and touring with Lady Gaga, Weezer, Pharrell, and Blink 182. In 2011, D.A. stopped touring in order to focus on his other passion, investing. He has since built a parallel career as a venture capitalist, backing a series of industry-defining technology companies including Spotify, SpaceX, Ripple, The Boring Company, and Memphis Meats. Since 2015, D.A. has focused on biotechnology and healthcare, seeking to reinvent medicine through breakthrough start-ups like Beam, Glympse, Doctor on Demand, Devoted Health, and Neuralink. Through caring for his late wife, Liz, and his extended family, he has experienced the best and the worst of American medicine, and is a passionate advocate for patients.

Heidi Wagner is a Global Executive and Government Affairs Expert with the rare combination of exceptional communications skills, legal and policy expertise, and business acumen. Her deep experience in government policy, product funding and pricing, patient advocacy and international management in the Biopharmaceutical Industry has made her a visionary partner and trusted advisor of top management and boards of directors. She is a thoughtful leader who empowers and guides employees to achieve goals, succeed in their roles and be recognized for outstanding service.